Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: Technical review and practice guidelines

Annals of Saudi Medicine

Volumn 32, Issue 2, 2012, Pages 174-199

  Abdo, Ayman A ^a   Hassanain, Mazen ^a,g   AlJumah, Abdul Rahman ^b   Al Olayan, Ashwaq ^b   Sanai, Faisal M ^b   Al Alsuhaibani, Hamad ^c   AbdulKareem, Huda ^d   Abdallah, Khalid ^b   AlMuaikeel, Mohammad ^b   Al Saghier, Mohammad ^e   Babatin, Mohammad ^f   Kabbani, Monther ^c   Bazarbashi, Shouki ^c   Metrakos, Peter ^g   Bruix, Jordi ^h  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d KING FAHAD MEDICAL CITY   (Saudi Arabia)

^e KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^f KING FAHAD GENERAL HOSPITAL   (Saudi Arabia)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALPHA FETOPROTEIN; BEVACIZUMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; IODINATED POPPYSEED OIL; LAMIVUDINE; MICROSPHERE; OXALIPLATIN; PEGINTERFERON; PLACEBO; PROTEIN P53; RIBAVIRIN; SORAFENIB; SUNITINIB; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABLATION THERAPY; ALCOHOLISM; ANOREXIA; ARTICLE; BLEEDING; CACHEXIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLON METASTASIS; COST EFFECTIVENESS ANALYSIS; CRYOABLATION; DIAGNOSTIC VALUE; DIARRHEA; DISEASE ASSOCIATION; ECHOGRAPHY; EVIDENCE BASED PRACTICE; FATIGUE; FEVER; GENETIC ASSOCIATION; HAND FOOT SYNDROME; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; ILEUS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MINIMALLY INVASIVE PROCEDURE; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIDETECTOR COMPUTED TOMOGRAPHY; NAUSEA; NEEDLE BIOPSY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION INDUCED EMESIS; RADIATION PNEUMONIA; RADIOFREQUENCY ABLATION; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RISK FACTOR; SAUDI ARABIA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SURGEON; SYSTEMATIC REVIEW (TOPIC); ULCER; WEIGHT REDUCTION;

CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; SAUDI ARABIA;

EID: 84865528020     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2012.174     Document Type: Article

References (215)

1. Abdo AA, Karim HA, Al Fuhaid T, Sanai FM, Kabbani M, Al Jumah A, et al. Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Ann Saudi Med. 2006 Jul-Aug;26(4):261-5. (Pubitemid 44679984)
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLO BOC AN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917.
3. Stewart B, Kleihues P, editors. World Cancer Report. Lyon: IARC Press; 2003.
4. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-85. (Pubitemid 29488770)
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745-50. (Pubitemid 29114292)
6. Kingdom of Saudi Arabia Ministry of Health. Saudi Cancer Registry. 2006.
7. al-Faleh FZ, Ayoola EA, Arif M, Ramia S, al-Rashed R, al-Jeffry M, et al. Seroepidemiology of hepatitis B virus infection in Saudi Arabian children: a baseline survey for mass vaccination against hepatitis B. J Infect. 1992 Mar;24(2):197-206.
8. Al-Faleh FZ, Al-Jeffri M, Ramia S, Al-Rashed R, Arif M, Rezeig M, et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect. 1999 May;38(3):167-70. (Pubitemid 29317385)
9. Madani TA. Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance. Ann Saudi Med. 2007 May-Jun;27(3):191-4. (Pubitemid 47062285)
10. Kingdom of Saudi Arabia Ministry of Health Statistics. 2009.
11. Kingston M, Ali MA, Lewall D. Hepatic tumors in Saudi Arabia. A practical approach to diagnosis. Cancer. 1985 Apr 1;55(7):1579-85. (Pubitemid 15140697)
12. Ashraf SJ, Arya SC, el-Sayed M, Sahay R, Parande CM, Tajuddin MR, et al. A profile of primary hepatocellular carcinoma patients in the Gizan Area of Saudi Arabia. Cancer. 1986 Nov 1;58(9):2163-8. (Pubitemid 16008801)
13. Atiyeh M, Ali MA. Primary hepatocelluar carcinoma in Saudi Arabia. A clinicopathological study of 54 cases. Am J Gastroenterol. 1980 Jul;74(1):25-9. (Pubitemid 10020821)
14. The Saudi Observatory Liver Disease Registry [database on the Internet] 2009 [cited 20 April 2010]. Available from: http://www.solid-registry.com/home. html.
15. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991 Sep 5;325(10):675-80.
16. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004 May;53(5):744-9. (Pubitemid 38561455)
17. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002 Nov;97(11):2886-95. (Pubitemid 35265444)
18. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 2001 Apr;82(2):77-100. (Pubitemid 32681936)
19. Kew M. Hepatic tumors and cysts. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2002.
20. Sanai FM, Sobki S, Bzeizi KI, Shaikh SA, Alswat K, Al-Hamoudi W, et al. Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig Dis Sci. 2010 Dec;55(12):3568-75.
21. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006 Jun 15;118(12):3030-44.
22. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology. 2008;75 Suppl 1:13-6.
23. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 1984 May;4(2):113-21.
24. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995 Jan;21(1):77-82.
25. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986 Feb;90(2):263-7.
26. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68. (Pubitemid 30143840)
27. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005 Feb 14;92(3):607-12. (Pubitemid 40395547)
28. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998 Jan 30;75(3):347-54. (Pubitemid 28100034)
29. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73. (Pubitemid 43042691)
30. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002 Dec;123(6):1848-56. (Pubitemid 35408309)
31. Abdo AA, Al-Jarallah BM, Sanai FM, Hersi AS, Al-Swat K, Azzam NA, et al. Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia. World J Gastroenterol. 2006 Nov 21;12(43):7019-24. (Pubitemid 44834894)
32. Colombo M. Malignant neoplasms of the liver. Schiff's Diseases of the Liver. 2003.
33. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129-33.
34. Sakuma K, Saitoh N, Kasai M, Jitsukawa H, Yoshino I, Yamaguchi M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology. 1988 Nov-Dec;8(6):1642-6. (Pubitemid 19021901)
35. Kew MC. Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: evidence from southern Africa. Hepatology. 1981 Jul-Aug;1(4):366-9. (Pubitemid 11024432)
36. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006 Nov 1;107(9):2212-22.
37. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2002 Sep;35(3):266-9. (Pubitemid 34913096)
38. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 Feb;112(2):463-72. (Pubitemid 27078833)
39. Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis. 2010 Jul;42 Suppl 3:S215-22.
40. Yu H, Harris RE, Kabat GC, Wynder EL . Cigarette smoking, alcohol consumption and primary liver cancer: a case-control study in the USA. Int J Cancer. 1988 Sep 15;42(3):325-8.
41. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol. 1994 Dec;21(6):1029-34.
42. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001 Nov 30;85(11):1700-5. (Pubitemid 34081516)
43. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, et al. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer. 1982 Feb 15;49(4):672-7. (Pubitemid 12165423)
44. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998 Jun;28(6):930-8. (Pubitemid 28275969)
45. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30. (Pubitemid 32844200)
46. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Lee PH, et al. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett. 2005 Apr 28;221(2):135-43. (Pubitemid 40460400)
47. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994;30A(3):344-50. (Pubitemid 24152476)
48. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001 Jan;12(1):13-21. (Pubitemid 32125897)
49. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-38. (Pubitemid 36459468)
50. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2054-60.
51. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985 Nov 14;313(20):1256-62. (Pubitemid 16217048)
52. Fargion S, Fracanzani AL, Piperno A, Braga M, D'Alba R, Ronchi G, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology. 1994 Dec;20(6):1426-31. (Pubitemid 24359051)
53. Polio J, Enriquez RE, Chow A, Wood WM, Atterbury CE . Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J Clin Gastroenterol. 1989 Apr;11(2):220-4. (Pubitemid 19104448)
54. Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer. 1989 Jun 1;63(11):2207-10. (Pubitemid 19136856)
55. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992 Jul;16(1):132-7.
56. Kew MC, Geddes EW. Hepatocellular carcinoma in rural southern African blacks. Medicine (Baltimore). 1982 Mar;61(2):98-108. (Pubitemid 12158546)
57. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J. 1971 Nov 13;4(5784):408-11.
58. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001 Feb;48(2):251-9. (Pubitemid 32141852)
59. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul;30(1):37-47.
60. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2.
61. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003 Oct;38(4):1034-42. (Pubitemid 37221687)
62. Yu JS, Kim KW, Kim EK, Lee JT, Yoo HS. Contrast enhancement of small hepatocellular carcinoma: usefulness of three successive early image acquisitions during multiphase dynamic MR imaging. AJR Am J Roentgenol. 1999 Sep;173(3):597-604. (Pubitemid 29395274)
63. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008 Jan;47(1):97-104. (Pubitemid 351171046)
64. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology. 1986 Jul-Aug;6(4):729-38. (Pubitemid 16038197)
65. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET . Radiology. 2003 Feb;226(2):533-42. (Pubitemid 36313446)
66. Chalasani N, Horlander JC, Sr., Said A, Hoen H, Kopecky KK, Stockberger SM, Jr., et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol. 1999 Oct;94(10):2988-93. (Pubitemid 29482770)
67. Yamashita Y, Takahashi M, Baba Y, Kanazawa S, Charnsangavej C, Yang D, et al. Hepatocellular carcinoma with or without cirrhosis: a comparison of CT and angiographic presentations in the United States and Japan. Abdom Imaging. 1993;18(2):168-75. (Pubitemid 23165935)
68. Mitsuzaki K, Yamashita Y, Ogata I, Nishiharu T, Urata J, Takahashi M. Multiple-phase helical CT of the liver for detecting small hepatomas in patients with liver cirrhosis: contrast-injection protocol and optimal timing. AJR Am J Roentgenol. 1996 Sep;167(3):753-7. (Pubitemid 26279730)
69. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12. (Pubitemid 39423377)
70. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50. (Pubitemid 38124619)
71. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002 Mar;97(3):734-44. (Pubitemid 34245906)
72. Sato Y, Sekine T, Ohwada S. Alpha-fetoproteinproducing rectal cancer: calculated tumor marker doubling time. J Surg Oncol. 1994 Apr;55(4):265-8. (Pubitemid 24143299)
73. Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology. 2003;65(2):95-101. (Pubitemid 37025967)
74. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol. 2001 Aug;35(2):254-8. (Pubitemid 32803481)
75. Torzilli G, Minagawa M, Takayama T, Inoue K, Hui A-M, Kubota K, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology. 1999;30(4):889-93. (Pubitemid 29458276)
76. Kanematsu T, Sonoda T, Takenaka K, Matsumata T, Sugimachi K, Inokuchi K. The value of ultrasound in the diagnosis and treatment of small hepatocellular carcinoma. Br J Surg. 1985 Jan;72(1):23-5. (Pubitemid 15158856)
77. Frazer C. Imaging of hepatocellular carcinoma. J Gastroenterol Hepatol. 1999 Aug;14(8):750-6. (Pubitemid 29426407)
78. Bizollon T, Rode A, Bancel B, Gueripel V, Ducerf C, Baulieux J, et al. Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol. 1998 Mar;28(3):491-6. (Pubitemid 28133554)
79. Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, Chen DS. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma-a study based on 420 patients. J Hepatol. 1996 Sep;25(3):334-8.
80. Horigome H, Nomura T, Saso K, Itoh M, Joh T, Ohara H. Limitations of imaging diagnosis for small hepatocellular carcinoma: comparison with histological findings. J Gastroenterol Hepatol. 1999 Jun;14(6):559-65. (Pubitemid 29281878)
81. Torzilli G. Japanese approach to hepatocellular carcinoma. Dig Liver Dis. 2001 Mar;33(2):118-20. (Pubitemid 32294170)
82. Longchampt E, Patriarche C, Fabre M. Accuracy of cytology vs. microbiopsy for the diagnosis of well-differentiated hepatocellular carcinoma and macroregenerative nodule. Definition of standardized criteria from a study of 100 cases. Acta Cytol. 2000 Jul-Aug;44(4):515-23. (Pubitemid 30640318)
83. Takamori R, Wong LL, Dang C, Wong L. Needletract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl. 2000 Jan;6(1):67-72. (Pubitemid 30123370)
84. Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol. 1994 Jan;20(1):117-21. (Pubitemid 24043096)
85. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003 May;52 Suppl 3:iii1-8.
86. Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005 Jul;42(1):27-34. (Pubitemid 40911308)
87. Kim SE, Lee HC, Shim JH, Park HJ, Kim KM, Kim PN, et al. Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area. Liver International. 2011:no-no.
88. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol. 2010 Mar;105(3):599-609.
89. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002 Mar 15;20(6):1527-36. (Pubitemid 34260532)
90. Fleming ID. AJCC/TN M cancer staging, present and future. J Surg Oncol. 2001 Aug;77(4):233-6. (Pubitemid 32744190)
91. Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006 Sep;41(9):884-92. (Pubitemid 44594230)
92. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985 Aug 15;56(4):918-28. (Pubitemid 15228292)
93. CLIP Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology. 1998;28(3):751-5.
94. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002 May;122(6):1609-19. (Pubitemid 34533556)
95. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000 Dec 1;89(11):2266-73.
96. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31(4):840-5.
97. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001 Sep;34(3):529-34. (Pubitemid 32786644)
98. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38.
99. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005 Apr;41(4):707-16. (Pubitemid 40462931)
100. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005 Mar;54(3):411-8. (Pubitemid 40299100)
101. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9. (Pubitemid 26079803)
102. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005 May;128(6):1752-64. (Pubitemid 40692563)
103. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun;33(6):1394-403. (Pubitemid 32496976)
104. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999 Dec;30(6):1434-40.
105. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TN M staging system for patients with hepatoma predictive of outcome? Cancer. 2000 Feb 1;88(3):538-43. (Pubitemid 30056926)
106. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002 Apr;235(4):533-9. (Pubitemid 34258353)
107. Steinmuller T, Pascher A, Sauer I, Theruvath T, Muller A, Settmacher U, et al. Living-donation liver transplantation for hepatocellular carcinoma: time to drop the limitations? Transplant Proc. 2002 Sep;34(6):2263-4. (Pubitemid 35299739)
108. Kawasaki S. Living-donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology. 2002 Jan-Feb;49(43):53-5. (Pubitemid 34289486)
109. Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNO S priority criteria. Ann Surg. 2004 Feb;239(2):142-9. (Pubitemid 38176346)
110. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004 Sep;240(3):451-9; discussion 9-61.
111. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008 Jul;14(7):935-45. (Pubitemid 352003892)
112. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007;25(4):310-2. (Pubitemid 350014958)
113. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology. 2001 May;33(5):1073-9. (Pubitemid 32378205)
114. Cheng SJ, Pratt DS, Freeman RB, Jr., Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation. 2001 Sep 15;72(5):861-8. (Pubitemid 32879859)
115. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004 Nov;240(5):900-9. (Pubitemid 39425785)
116. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002 Jan;50(1):123-8. (Pubitemid 34028315)
117. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003 Jun;9(6):557-63. (Pubitemid 36701690)
118. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004 Mar;10(3):449-55. (Pubitemid 38380323)
119. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997 Dec;226(6):688-701; discussion -3.
120. Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant. 2005 Apr;5(4 Pt 1):788-94. (Pubitemid 40461289)
121. Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60. (Pubitemid 39423394)
122. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001 Jul;234(1):63-70. (Pubitemid 32619336)
123. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995 Mar;221(3):291-8.
124. Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg. 1995 Jan-Feb;19(1):35-41.
125. Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2003 Jan;1(1):10-8. (Pubitemid 37254467)
126. Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S259-63.
127. Dodd GD, 3rd, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics. 2000 Jan-Feb;20(1):9-27.
128. Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 1995 May;22(5):522-6.
129. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis. 1999;19(3):323-8. (Pubitemid 29488774)
130. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer. 1996 May 1;77(9):1792-6. (Pubitemid 26125178)
131. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992 Feb 15;69(4):925-9.
132. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995 Oct;197(1):101-8.
133. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 1993 Nov;18(5):1121-6. (Pubitemid 23320442)
134. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol. 1993 May;160(5):1023-8. (Pubitemid 23141242)
135. Castellano L, Calandra M, Del Vecchio Blanco C, de Sio I. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol. 1997 Nov;27(5):862-70. (Pubitemid 27454830)
136. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. Journal of hepatology. 2010;52(3):380-8.
137. Choti MA. Surgical management of hepatocellular carcinoma: resection and ablation. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S197-203.
138. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000 Sep;232(3):381-91.
139. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999 Mar;210(3):655-61. (Pubitemid 29124024)
140. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003 Jul;228(1):235-40. (Pubitemid 36736097)
141. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009 Feb;104(2):514-24.
142. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology. 2004 Dec;127(6):1714-23.
143. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2004(2):CD003046.
144. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective
145. Huang JW, Hernandez-Alejandro R, Croome KP, Yan LN, Wu H, Chen ZY, et al. Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations. World J Gastroenterol. 2011 Jan 7;17(1):123-9.
146. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001 May;33(5):1124-9. (Pubitemid 32378211)
147. Castells A, Bruix J, Ayuso C, Bru C, Montanya X, Boix L, et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol. 1995 Apr;22(4):410-5.
148. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S179-88. (Pubitemid 39423386)
149. Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol. 1999 Oct;94(10):3028-33. (Pubitemid 29482777)
150. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol. 1995 Jul;7(7):627-33.
151. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;3:CD004787.
152. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9. (Pubitemid 34607087)
153. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71. (Pubitemid 34454013)
154. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429-42. (Pubitemid 36152543)
155. Al Fuhaid T, Al Madi M, Al Abdul Kareem H, Al Dukhayil M, Abdo AA. Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma. Saudi J Gastroenterol. 2007 Jan-Mar;13(1):21-4.
156. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008 Mar-Apr;31(2):269-80.
157. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007 Mar;46(3):474-81. (Pubitemid 46201723)
158. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8.
159. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECI SION V study. Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52.
160. Ali SM. Radioembolization for hepatocellular carcinoma using TheraSphere(R). Saudi J Gastroenterol. 2011 May-Jun;17(3):215-7.
161. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006 Oct;17(10):1571-93. (Pubitemid 44596135)
162. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006 Dec 1;94(7):572-86. (Pubitemid 44851918)
163. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008 Jan;47(1):71-81. (Pubitemid 351171043)
164. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival. Hepatology. 2010 Nov;52(5):1741-9.
165. Abaalkhail F, Al-Hamoudi W, Al Sebayel M, Alsuhaibani H, Kamel Y, Khalaf H, et al. Safety and Efficacy of Yttrium-90 Microspheres for the Treatment of Hepatocellular Carcinoma: A Single Center Experience. Journal of hepatology. 2011;54:S252.
166. Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mossner J, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol. 2000 Jan;11(1):113-4. (Pubitemid 30084591)
167. Gebbia V, Maiello E, Serravezza G, Giotta F, Testa A, Borsellino N, et al. 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Anticancer Res. 1999 Mar-Apr;19(2B):1407-10. (Pubitemid 29257467)
168. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis? Aliment Pharmacol Ther. 1998 Feb;12(2):111-26. (Pubitemid 28059978)
169. Ben Mousa A. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol. 2008 Jan;14(1):40-2.
170. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44. (Pubitemid 44480537)
171. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. (Pubitemid 46630787)
172. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90.
173. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34.
174. Abou-Alfa G, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CP B) cirrhosis? J Clin Oncol. [Abstract]. 2008;26(May 20 suppl):4518.
175. Abou-Alfa G, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) . Gastrointestinal Cancers Symposium; Orlando, FL2008: 128
176. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711.
177. Rimassa L, Santoro A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig Liver Dis. 2010 Jul;42 Suppl 3:S273-80.
178. Thongprasert S, Qin S, Lim H, Bhudhisawasdi V, Yin X, Gang W, et al. Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin (FOL FOX4) versus doxorubicin in advanced HCC : Updates on the EACH study. J Clin Oncol 2011 29(suppl 4):abstr 160.
179. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997 Jun 26;336(26):1855-9.
180. AlFaleh F, AlShehri S, AlAnsari S, AlJeffri M, AlMazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. Journal of Infection. 2008;57(5):404-9.
181. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74.
182. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995 Oct 21;346(8982):1051-5.
183. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999 Apr;29(4):1124-30. (Pubitemid 29168746)
184. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999 Jun;29(6):1870-5. (Pubitemid 29247063)
185. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998 May;27(5):1435-40. (Pubitemid 28227875)
186. Esteban R. Can interferon prolong life? Hepatology. 2003 Aug;38(2):292-4. (Pubitemid 36919849)
187. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 1999 Nov 2;131(9):696-701. (Pubitemid 29517956)
188. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001 Apr;34(4):593-602. (Pubitemid 32328518)
189. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2001 May;15(5):689-98. (Pubitemid 32385874)
190. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004 Mar 16;140(6):465-79.
191. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar;140(3):840-9; quiz e12.
192. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr;53(4):1100-8.
193. Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al. Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. Gastroenterology. 2011 Mar 17;[E-pub ahead of print].
194. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999 Aug 3;131(3):174-81. (Pubitemid 29364999)
195. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998 Jul 15;129(2):94-9. (Pubitemid 28337250)
196. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 1999 Apr;30(4):653-9. (Pubitemid 29151907)
197. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S303-9. (Pubitemid 39423400)
198. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999 Mar;29(3):971-5.
199. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.
200. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998 Jan;27(1):273-8. (Pubitemid 28041564)
201. Sarasin FP, Giostra E, Hadengue A. Costeffectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996 Oct;101(4):422-34. (Pubitemid 26392861)
202. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22.
203. Tang ZY, Yu YQ, Zhou XD, Yang BH, Ma ZC, Lin ZY. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl.1993;3:55-8.
204. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995 Aug;22(2):432-8.
205. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003 Mar;37(3):520-7. (Pubitemid 36258772)
206. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003 Mar;98(3):679-90. (Pubitemid 36348544)
207. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98(7):1166-75. (Pubitemid 351481685)
208. Zaman SN, Johnson PJ, Williams R. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer. 1990 Apr 1;65(7):1607-10. (Pubitemid 20106123)
209. Sherman M. Alphafetoprotein: an obituary. Journal of hepatology. 2001;34(4):603-5. (Pubitemid 32328519)
210. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gammacarboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb;138(2):493-502.
211. Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S104-7. (Pubitemid 39423376)
212. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 2000 Jun;95(6):1535-8. (Pubitemid 30396316)
213. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood. 2003 Jul 1;102(1):78-82. (Pubitemid 36759638)
214. Kim D, Han K, Sang H, al. e. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience). Hepatology. 2007;46:403A.
215. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010 Aug;53(2):291-7.